The UMR-S-1064 INSERM unit in Nantes comprises laboratories (2000 m2) as well as rodent (500 m2), primate and pig (250 m2) animal facilities. Clinical and research areas as well as meeting and teaching rooms are housed in the same building which is located within the Nantes University Hospital. The INSERM U1064 has presently a staff comprised of 165 people organised into 6 teams. The INSERM U1064 scientific strategy is based on the following principles: -integration between molecular, cellular and in vivo approaches, -strong interaction between basic, translational and clinical research. 7 patents were registered by INSERM U1064 since 2000 in our own team. Together with the Nantes University Hospital Department of Nephrology, Transplantation and Urology, INSERM U1064 forms the ITUN (Institut Transplantation Urologie Nephrologie). It comprises two pre-clinical platforms devoted to experimentation in large animals: primates (baboons, macaques) and genetically modified pigs.
The UMR-S-1064 INSERM unit participated at several European programs. Two of them are directly devoted to “drug free tolerant patients”: “RISET”: Reprogramming the Immune System for the Establishment of Tolerance (starting date : May 2005) and “Indices of Tolerance” (starting date : January 2003). Finally, ITERT is a member of the European Society for Organ Transplantation (ESOT) and is a “Centre of Excellence” of the Federation of Clinical Immunology Societies (FOCIS). FOCIS participates to the development and the knowledge transfer of clinical immunology research through the organisation of courses, scientific meetings and networks.
Two private bio-companies have been initiated from the INSERM Unit: TcLand Expression and Effimune, which are both devoted to the discovery of new biomarkers and therapeutic targets in the clinic. Jean Paul Soulillou and Sophie Brouard, are founders and consultants for these companies.
During the TRANSLINK PROJECT we will investigate possible modifications of the phenotype, level of mRNA and miRNA of human endothelial cells induced by anti-Neu5Gc. Anti-neu5Gc antibodies will be tested in a human in vitro assay modeling the transfer of resting or activated T, B lymphocytes and monocytes through endothelial cells. The objectives of these studies are to obtain new molecular information on the role of anti-Neu5Gc in inflammation in the endothelium. We aim to correlate the presence of Neu5Gc with Ig, C4d deposits and CD55 on various normal tissues and to test the specificity of eluted Ig for Neu5Gc in tissues from normal donors and recipients of HBV. The group is familiar and already published several reports with the technology proposed.
Contributors to TRANSLINK:
- Sophie Brouard, PhD, director of research in the INSERM U1064
- Sophie Conchon, PhD, researcher at INSERM U1064,
- Jean-Paul Soulillou, Professor, member of the “institut universitaire de France”
- Ludmilla Le Berre, PhD, post-doctoral fellow in the INSERM U1064